In light of the centrality of the PTGS2 gene in the interactome network and the known importance of its gene product cyclooxygenase-2 (COX-2) in the survival and metastasis of cancer cells and its potential clinical impact given the availability of pharmacologic tools to inhibit its enzymatic function [21], we sought to investigate its role in EGFR-mutant NSCLC cells. The gene discussed is EGFR; the disease is cancer.